Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-07-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ulnventricularcardiacdiseasepatient
  Phrases that lowered it: breast cancerher2women withneoadjuvantnegative breast
• Maximum age: 120 (lowers risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 4.9% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Number of arms: 1 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 22.9% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 5892 (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 11 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 29063 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer NCT02003209 · started 2014 · scored riskier than 84% of active trials completed
• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer NCT01275677 · started 2011 · scored riskier than 47% of active trials completed
• Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer NCT01022138 · started 2010 · scored riskier than 83% of active trials terminated
• Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer NCT01959490 · started 2013 · scored riskier than 68% of active trials completed
• Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer NCT00820872 · started 2009 · scored riskier than 84% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.